Jade Biosciences to Present New Preclinical Data on JADE101 at the 62nd European Renal Association Congress

Core Viewpoint - Jade Biosciences is advancing its investigational anti-APRIL monoclonal antibody, JADE101, for the treatment of IgA nephropathy, with new preclinical data to be presented at the 62nd European Renal Association Congress [1][2]. Company Overview - Jade Biosciences, Inc. is a biotechnology company focused on developing therapies for autoimmune diseases, with its lead candidate, JADE101, targeting the cytokine APRIL for IgA nephropathy [5]. - The company plans to initiate a first-in-human clinical trial for JADE101 in the second half of 2025 [5]. Product Details - JADE101 is designed to reduce pathogenic IgA levels, decrease proteinuria, and preserve kidney function in patients with IgA nephropathy [4]. - The antibody is engineered with half-life extension technology, allowing for dosing at intervals of at least eight weeks, enhancing patient convenience [4]. Upcoming Events - Jade Biosciences will host a conference call and webcast on June 9, 2025, to discuss the new data on JADE101 presented at the ERA Congress [2][3]. - The presentation titled "Discovery and Characterization of JADE101" will occur during the Focused Oral Session on Glomerular and Tubulo-Interstitial Diseases on June 6, 2025 [6].